Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab

S.J.A.M. Santegoets; A.G.M. Stam; S.M. Lougheed; H. Gall; K. Jooss; N. Sacks; K. Hege; I. Lowy; R.J. Scheper; W.R. Gerritsen; A.J.M. van den Eertwegh; T.D. de Gruijl

doi:10.1186/s40425-015-0061-5

Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab

S.J.A.M. Santegoets, A.G.M. Stam, S.M. Lougheed, H. Gall, K. Jooss, N. Sacks, K. Hege, I. Lowy, R.J. Scheper, W.R. Gerritsen, A.J.M. van den Eertwegh, T.D. de Gruijl

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Article number	31
Journal	Journal for Immunotherapy of Cancer
Volume	2
DOIs	https://doi.org/10.1186/s40425-015-0061-5
Publication status	Published - 2014

Access to Document

10.1186/s40425-015-0061-5

http://dx.doi.org/10.1186/s40425-014-0031-3

Cite this

Santegoets, S. J. A. M., Stam, A. G. M., Lougheed, S. M., Gall, H., Jooss, K., Sacks, N., Hege, K., Lowy, I., Scheper, R. J., Gerritsen, W. R., van den Eertwegh, A. J. M., & de Gruijl, T. D. (2014). Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. Journal for Immunotherapy of Cancer, 2, [31]. https://doi.org/10.1186/s40425-015-0061-5

@article{b8f6bcc4ef0f4a79a851c9068d30c2ae,

title = "Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab",

author = "S.J.A.M. Santegoets and A.G.M. Stam and S.M. Lougheed and H. Gall and K. Jooss and N. Sacks and K. Hege and I. Lowy and R.J. Scheper and W.R. Gerritsen and {van den Eertwegh}, A.J.M. and {de Gruijl}, T.D.",

year = "2014",

doi = "10.1186/s40425-015-0061-5",

language = "Undefined/Unknown",

volume = "2",

journal = "Journal for Immunotherapy of Cancer",

issn = "2051-1426",

publisher = "BioMed Central",

}

Santegoets, SJAM, Stam, AGM , Lougheed, SM, Gall, H, Jooss, K, Sacks, N, Hege, K, Lowy, I, Scheper, RJ, Gerritsen, WR, van den Eertwegh, AJM & de Gruijl, TD 2014, 'Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab', Journal for Immunotherapy of Cancer, vol. 2, 31. https://doi.org/10.1186/s40425-015-0061-5

TY - JOUR

T1 - Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab

AU - Santegoets, S.J.A.M.

AU - Stam, A.G.M.

AU - Lougheed, S.M.

AU - Gall, H.

AU - Jooss, K.

AU - Sacks, N.

AU - Hege, K.

AU - Lowy, I.

AU - Scheper, R.J.

AU - Gerritsen, W.R.

AU - van den Eertwegh, A.J.M.

AU - de Gruijl, T.D.

PY - 2014

Y1 - 2014

U2 - 10.1186/s40425-015-0061-5

DO - 10.1186/s40425-015-0061-5

M3 - Article

SN - 2051-1426

VL - 2

JO - Journal for Immunotherapy of Cancer

JF - Journal for Immunotherapy of Cancer

M1 - 31

ER -